← MoonLake Immunotherapeutics (MLTX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
MoonLake Immunotherapeutics (MLTX)
Pharmaceutical Preparations · market cap $1.1B · as of 2026-07-19
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-04 (est.)
Earnings
Pipeline
3
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
MoonLake Immunotherapeutics (MLTX) is a clinical-stage pharmaceutical company with ~100 employees and a $1.45B market cap, built around sonelokimab, a nanobody in Phase 3 development for Hidradenitis Suppurativa (HS). The company has no revenue, a 13.5-month cash runway on $298.5M in cash, and a pivotal Phase 3 sonelokimab readout expected around September 2026 that represents an existential binary event.
The catalyst path
- 2026-11-04 (est.)Earningsimp 5/10
- 2027-01-15 (est.)Phase 3 · Risankizumabimp 9/10
- 2027-02-17 (est.)PDUFAimp 8/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Sonelokimab | Phase 3 | Hidradenitis Suppurativa |
| Risankizumab | Phase 3 | Arthritis, Psoriatic |
| Sonelokimab (M1095) | Phase 2 | Hidradenitis Suppurativa |
Price & technical context
3-month
-39.5%
6-month
-30.6%
12-month
+60.0%
52-wk range
$7.06–$22.16
vs 50-day MA
-25.1%
vs 200-day MA
-31.7%
Realized vol
70.8%
Max drawdown
-89.9%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for MLTX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.